Background: This case report aims to describe the impact of the bidirectional chemotherapy (BDC) on resecability for initially unresectable malignant peritoneal mesothelioma (MPM). Methods: We report a case of 55-year-old male with the diagnosis of initially unresecable MPM. The BDC combined intravenous (IV) chemotherapy (Cisplatin-Pemetrexed) and intra peritoneal (IP) chemotherapy (Cisplatin). The response to chemotherapy was assessed by CTscan and laparoscopy. Results: Initial evaluation classed the disease as unresecable with PCI at 39. At the reevaluation, CTscan and laparoscopy showed a macroscopic response, allowing surgery consisting of cytoreductive surgery and hyperthermic intra peritoneal chemotherapy (Doxorubicin and Cisplatin). Conclusions: BDC (IV and IP) has promising results and allows to undergo surgery for selected patients with borderline or initially unresectable MPM. Figure 3: CT scan (A) and laparoscopic evaluation (B) after bi-directional chemotherapy.
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We report a case of 55-year-old male with the diagnosis of malignant peritoneal mesothelioma (MPM). Initial evalua-tion with CT-scan and laparoscopy reveals unresectable peritoneal carcinomatosis with PCI at 39 with thickened omentum (star), small bowel (2 stars) and parietal peritoneum (dash-arrow) deposit, ascitis (plane-arrow) ( Figure 1A, B ). Bidirectional chemotherapy (BDC) has been performed after three cycles of intravenous (IV) Cisplatin-Pemetrexed, with intensification combining three cycles of IV Pemetrexed with intraperitoneal (IP) Cisplatin (Figure 2 ). At reevaluation, PCI was still at 39 with a macroscopic response ( Figure 3A , B). The peritoneal disease was thinner allowing a complete CRS with Doxorubicin/Cisplatin based-HIPEC.
BDC allowed selecting patients with initially unresectable MPM to undergo surgery and increase the overall survival (OS) [1, 2] . New IP delivery with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) reported promising results in palliative treatment of MMP [3] and is under evaluation to increase OS and secondary resectability of huge MMP (Clinical Trials NCT03875144).
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